Shire Accepts Improved $62B Bid From Takeda
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
Ireland’s Shire Buys Baxalta for $32 Billion
The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
Shire to Buy Rival Drug Maker Dyax for $5.9B
The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
Another Tax Inversion Deal in the Works
The hue and cry over tax inversions is not stopping companies from proceeding with more mergers that take advantage of the tactic.